FINWIRES · TerminalLIVE
FINWIRES

Update: Personalis Shares Rise After NeXT Disease Test Approved for Expanded Coverage by Medicare, Medicaid

By

(Updates with recent stock movement in the headline and the first paragraph.)

Personalis (PSNL) shares rose 9% in Wednesday afternoon trading after the company said its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.

The approval is for monitoring treatment response to neoadjuvant therapy in patients diagnosed with Stage II-III triple-negative breast cancer or HER2-positive breast cancer, it said Wednesday.

The coverage decision was backed by clinical evidence from a 227-patient study showing monitoring with NeXT allows accurate tracking of therapy response, outperforming standard clinical metrics, the company said.

Price: $7.67, Change: $+0.63, Percent Change: +8.95%

Related Articles

Wire

Roblox Launches First-Ever Share Repurchase Program

Roblox (RBLX) said Tuesday that its board has authorized a repurchase program of up to $3 billion of its common stock, with the intent to buy back up to $1 billion of stock over the next 12 months.This represents the company's first-ever share repurchase program, according to a statement.Shares of the company were up 4% in after-hours trading.

$RBLX
Wire

Relay Therapeutics Launches $175 Million Stock Offering; Shares Drop After Hours

Relay Therapeutics (RLAY) launched an underwritten public offering of $175 million of common stock.Underwriters are set to receive a 30-day option to buy up to an additional 15% of the offering, the company said Tuesday in a statement.Relay shares fell 4.1% in after-hours trading.

$RLAY
Wire

Keysight Technologies Fiscal Q2 Non-GAAP Earnings, Revenue Rise; Sets Q3 Guidance; Shares Gain After-Hours

Keysight Technologies (KEYS) reported fiscal Q2 non-GAAP net income late Tuesday of $2.87 per diluted share, up from $1.70 a year earlier.Analysts polled by FactSet expected $2.32.Revenue for quarter ended April 30 rose to $1.72 billion from $1.31 billion a year earlier.Analysts surveyed by FactSet expected $1.71 billion.The company expects fiscal Q3 non-GAAP EPS of $2.43 to $2.49 on revenue of $1.73 billion to $1.75 billion. Analysts expect $2.16 and $1.65 billion, respectively.Shares of Keysight Technologies were up almost 9% in after-hours activity.

$KEYS